Network meta-analyses comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis at 24–28 and 48–52 weeks

References

• Rigopoulos D, Stathopoulou A, Gregoriou S. Small molecules and biologics in the treatment of nail psoriasis. Skin Appendage Disord. 2020;6(3):1–5. doi:10.1159/000507298.
   PubMed Web of Science ®Google Scholar
• Sobolewski P, Walecka I, Dopytalska K. Nail involvement in psoriatic arthritis. Reumatologia. 2017;55(3):131–135. doi:10.5114/reum.2017.68912.
   PubMedGoogle Scholar
• Haneke E. Nail psoriasis: clinical features, pathogenesis, differential diagnoses, and management. Psoriasis (Auckl). 2017;7:51–63. doi:10.2147/PTT.S126281.
   PubMed Web of Science ®Google Scholar
• Jiaravuthisan MM, Sasseville D, Vender RB, et al. Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy. J Am Acad Dermatol. 2007;57(1):1–27. doi:10.1016/j.jaad.2005.07.073.
   PubMed Web of Science ®Google Scholar
• Wilson FC, Icen M, Crowson CS, et al. Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study. Arthritis Rheum. 2009;61(2):233–239. Erratum in: arthritis Rheum. 2010;62(4):574. PMID: 19177544; PMCID: PMC3061343. doi:10.1002/art.24172.
   PubMed Web of Science ®Google Scholar
• Yan D, Ahn R, Leslie S, et al. Clinical and genetic risk factors associated with psoriatic arthritis among patients with psoriasis. Dermatol Ther (Heidelb). 2018;8(4):593–604. doi:10.1007/s13555-018-0266-x.
   PubMed Web of Science ®Google Scholar
• Szebényi J, Gede N, Hegyi P, et al. Efficacy of biologics targeting tumour necrosis factor-alpha, interleukin-17 -12/23, -23 and small molecules targeting JAK and PDE4 in the treatment of nail psoriasis: a network meta-analysis. Acta Derm Venereol. 2020;100(18):adv00318. doi:10.2340/00015555-3640.
   PubMedGoogle Scholar
• Huang IH, Wu PC, Yang TH, et al. Small molecule inhibitors and biologics in treating nail psoriasis: a systematic review and network meta-analysis. J Am Acad Dermatol. 2021;85(1):135–143. doi:10.1016/j.jaad.2021.01.024.
   PubMed Web of Science ®Google Scholar
• Reich K, Conrad C, Kristensen LE, et al. Network meta-analysis comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis. J Dermatolog Treat. 2022;33(3):1652–1660. doi:10.1080/09546634.2021.1892024.
   PubMed Web of Science ®Google Scholar
• Husein-ElAhmed H, Husein-ElAhmed S. Bayesian network meta-analysis of head-to-head trials for complete resolution of nail psoriasis. Clin Exp Dermatol. 2023;48(8):895–902. Apr 13:llad136. doi:10.1093/ced/llad136.
   PubMed Web of Science ®Google Scholar
• Elewski B, Rich P, Lain E, et al. Efficacy of brodalumab in the treatment of scalp and nail psoriasis: results from three phase 3 trials. J Dermatolog Treat. 2022;33(1):261–265. doi:10.1080/09546634.2020.1749546.
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Strober B, Menter A, et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 2015;373(14):1318–1328. doi:10.1056/NEJMoa1503824.
   PubMed Web of Science ®Google Scholar
• Elewski BE, Okun MM, Papp K, et al. Adalimumab for nail psoriasis: efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial. J Am Acad Dermatol. 2018;78(1):90–99.e1. doi:10.1016/j.jaad.2017.08.029.
   PubMed Web of Science ®Google Scholar
• Rich P, Griffiths CE, Reich K, et al. Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year. J Am Acad Dermatol. 2008;58(2):224–231. doi:10.1016/j.jaad.2007.07.042.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Papp K, Gottlieb A, IXORA-R study group., et al. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial. Br J Dermatol. 2020;182(6):1348–1358. doi:10.1111/bjd.18851.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Leonardi C, Elewski B, et al. A head-to-head comparison of ixekizumab versus guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomised, double-blinded trial. Br J Dermatol. 2021;184(6):1047–1058. doi:10.1111/bjd.19509.
   PubMed Web of Science ®Google Scholar
• Wasel N, Thac ID, French LE, et al. Ixekizumab and ustekinumab efficacy in nail psoriasis in patients with moderateto-severe psoriasis: 52-week results from a phase 3, head-to-head study (IXORA-S). Dermatol Ther (Heidelb). 2020;10(4):663–670. doi:10.1007/s13555-020-00383-x.
   PubMed Web of Science ®Google Scholar
• Mease PJ, Smolen JS, Behrens F, et al. A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. Ann Rheum Dis. 2020;79(1):123–131. doi:10.1136/annrheumdis-2019-215386.
   PubMed Web of Science ®Google Scholar
• Smolen JS, Mease P, Tahir H, et al. Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52. Ann Rheum Dis. 2020;79(10):1310–1319. doi:10.1136/annrheumdis-2020-217372.
   PubMed Web of Science ®Google Scholar
• Foley P, Gordon K, Griffiths CEM, et al. Efficacy of guselkumab compared with adalimumab and placebo for psoriasis in specific body regions: a secondary analysis of 2 randomized clinical trials. JAMA Dermatol. 2018;154(6):676–683. doi:10.1001/jamadermatol.2018.0793.
   PubMed Web of Science ®Google Scholar
• Papp KA, Lebwohl M, Gottlieb AB, et al. Bimekizumab for the treatment of moderate to severe plaque psoriasis with scalp, nail and palmoplantar involvement through 52 weeks: post-hoc analysis from the BE VIVID phase 3 trial. Poster presented at: european Academy of Dermatology and Venereology (EADV) Virtual Congress; 2020 Oct 29–31.
   Google Scholar
• Reich K, Papp KA, Blauvelt A, et al. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo-controlled phase 3 trial. Lancet. 2021;397(10273):487–498. doi:10.1016/S0140-6736(21)00125-2.Erratum in: lancet. 2021;397:670.
   PubMed Web of Science ®Google Scholar
• Eyerich K, Gottlieb AB, Piaserico S, et al. Bimekizumab versus secukinumab for the treatment of nail psoriasis in patients with moderate to severe plaque psoriasis: results from the BE RADIANT phase 3b trial. Poster session 43878 presented at: American Academy of Dermatology (AAD) Conference; 2023 March 17–21; New Orleans, LA.
   Google Scholar
• Reich K, Warren RB, Lebwohl M, et al. Bimekizumab versus secukinumab in plaque psoriasis. N Engl J Med. 2021;385(2):142–152. doi:10.1056/NEJMoa2102383.
   PubMed Web of Science ®Google Scholar
• Warren RB, See K, Burge R, et al. Rapid response of biologic treatments of moderate-to-severe plaque psoriasis: a comprehensive investigation using bayesian and frequentist network meta-analyses. Dermatol Ther (Heidelb). 2020;10(1):73–86. doi:10.1007/s13555-019-00337-y.
   PubMed Web of Science ®Google Scholar
• Brooks SP, Gelman A. General methods for monitoring convergence of iterative simulations. J Comput Graphical Stat. 1998;7:434–455.
   Web of Science ®Google Scholar
• Dias S, Welton NJ, Sutton AJ, et al. NICE DSU technical support document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials. London (UK): National Institute for Health and Care Excellence (NICE); 2014. www.ncbi.nlm.nih.gov/books/NBK310366.
   Google Scholar
• Higgins JPT, Thomas J, Chandler J, et al. editors. Cochrane handbook for systematic reviews of interventions, version 6.3. Chichester (UK): John Wiley & Sons; 2022.
   Google Scholar
• Rusk AM, Fleischer AB.Jr. In psoriasis treatment, greater improvement in skin severity predicts greater improvement in nail severity. J Dermatolog Treat. 2021;32(8):894–897. doi:10.1080/09546634.2020.1720578.
   PubMed Web of Science ®Google Scholar
• Kristensen LE, Soliman AM, Papp K, et al. Effects of risankizumab on nail psoriasis in patients with active psoriatic arthritis: results from KEEPsAKE 1. J Eur Acad Dermatol Venereol. 2022;36(5):e389–e392. doi:10.1111/jdv.17931.
   PubMed Web of Science ®Google Scholar
• Galluzzo M, Talamonti M, Cioni A, et al. Efficacy of tildrakizumab for the treatment of difficult-to-treat areas: scalp, nail, palmoplantar and genital psoriasis. J Clin Med. 2022;11(9):2631. doi:10.3390/jcm11092631.
   PubMed Web of Science ®Google Scholar
• Sbidian E, Chaimani A, Garcia-Doval I, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. 2022;5(5):CD011535. PMID: 35603936; PMCID: PMC9125768. doi:10.1002/14651858.CD011535.pub5.
   PubMedGoogle Scholar
• Egeberg A, Kristensen LE, Vender R, et al. Sustained resolution of nail psoriasis through 5 years with ixekizumab: a post-hoc analysis from UNCOVER-3. Acta Derm Venereol. 2022;102:adv00787. doi:10.2340/actadv.v102.2269.
   PubMed Web of Science ®Google Scholar
• Seyger MMB, Reich A, El Baou C, et al. Efficacy of ixekizumab on nail psoriasis in paediatric patients with moderate-to-severe psoriasis: a post hoc analysis from IXORA-PEDS. J Eur Acad Dermatol Venereol. 2021;35(12):e911–e913. doi:10.1111/jdv.17564.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency: bimekizumab (Bimzelx®) summary of product characteristics. cited 2023 May 9]. Available from: https://www.ema.europa.eu/en/documents/product-information/bimzelx-epar-product-information_en.pdf.
   Google Scholar